[Is Schilling test necessary for the etiological diagnosis of B12 insufficiency?].

In the following article a comparative evaluation of the tests used for the causative investigation of vitamin B(12) deficiency is presented. Although Schilling test since 2003 is not available in the market, it is considered the gold standard as a functional test of vitamin B(12) absorption, as it not only has a high specificity for the diagnosis of pernicious anaemia but also examines both gastric and intestinal stage of vitamin B(12) absorption. Consequently restoration of Schilling test in the clinical setting is necessary for the etiological diagnosis of B(12) insufficiency at least until a new and better vitamin B(12) absorption test is approved.

Pernicious anemia associated with cryptogenic cirrhosis: Two case reports and a literature review.

RATIONALE: Pernicious anemia (PA) is an autoimmune gastritis that results from the destruction of gastric parietal cells and the associated lack of an intrinsic factor to bind ingested vitamin B12. While an association between PA and various liver diseases has been rarely reported, reports of associated diseases include primary biliary cholangitis, autoimmune hepatitis, and Interferon-treated hepatitis C. We present 2 cases of PA associated with cryptogenic cirrhosis (CC), which has not been previously reported in the literature. PATIENT CONCERNS: A 42-year-old man presented with fatigue, pallor, and sustained abdominal distension that had persisted for 15 days. An 87-year-old man was admitted to the hospital for an unsteady gait and loss of appetite that had persisted for 20 days. DIAGNOSES: Symptoms, laboratory tests, and imaging findings for both patients were indicative of PA and CC.Both had neurological and psychiatric symptoms during hospitalization that were ultimately linked to a vitamin B12 deficiency but not hepatic encephalopathy. INTERVENTIONS: Both patients received intramuscular injections of vitamin B12. OUTCOMES: Hemoglobin levels of the 2 patients increased gradually, and their neurological symptoms were alleviated. LESSONS: PA associated with a liver disease is rare, and the underlying mechanism can only now be clarified. We speculate that autoimmune dysfunction and chronic vitamin B12 deficiency caused by PA might be unique causes of liver cirrhosis. Additional investigations are needed to verify these findings.

Estimated radiation dose to breast feeding infant following maternal administration of 57Co labelled to vitamin B12.

Administration of a radiopharmaceutical may result in a radiation dose to an infant due to ingestion of the radiopharmaceutical secreted in the breast milk. Following a maternal administration of Co labelled to vitamin B12 (cyanocobalamin) as part of a Schilling test an estimate of the absorbed dose to a breast feeding infant was calculated. Milk samples were collected from every feed in the first 24 h, and at approximately 48 and 72 h post-administration. The absorbed dose to the infant's liver (the organ receiving the highest dose) was calculated to be 0.23 mGy. The effective dose to the infant was calculated to be 0.025 mSv, which is considerably lower than the current regulatory limit of 1 mSv. The Administration of Radioactive Substances Advisory Committee advise that the first feed, at approximately 4 h after administration, be discarded. The data show that this was unwarranted, and that the peak concentration of Co in the breast milk occurred at around 24 h.

Accuracy of measurement of dual-isotope Schilling test urine samples: a multicenter study [corrected].

UNLABELLED: As a component of our quality assurance program, this multicenter study was performed to characterize the magnitude and types of error present in measurement of typical dual-isotope Schilling test (DIST) urine samples. METHODS: A panel of three simulated DIST urine samples was formulated corresponding to diagnoses of normal excretion, malabsorption and pernicious anemia and was distributed to eight hospitals in our regional area (three novice and five experienced users). Count-rate data and urine volume measurements from each site were analyzed for accuracy against the predicted values and a carefully measured gold standard and were correlated with the methodology and equipment used. RESULTS: Three of 24 results were uninterpretable due to an overly low ratio of intrinsic factor bound to free vitamin B12 excretion (B/F ratio), inconsistent with possible diagnoses. In 20 of 21 interpretable samples, results corresponded to the appropriate diagnoses, with typical values noted in 18 of the cases and slightly atypical yet diagnostic values seen in the remaining two cases. In only one sample did values correspond to an erroneous diagnosis (low normal or partial malabsorption rather than pernicious anemia). The four major discrepancies (test failure or misdiagnosis) were largely attributable to blunders and were limited to two of the three novice sites and to a single experienced site which had grossly inaccurate raw data (background greater than sample counts). CONCLUSION: Quantitation of vitamin B12 excretion in DIST urine samples is a reliable method of evaluation when performed by reasonably experienced and competent clinical laboratories. Improved accuracy may be obtained by increasing the stochastic certainty of the count data and by more careful measurement of the sample and urine volumes.

Schilling evaluation of pernicious anemia: current status.

The Schilling examination remains a popular means of evaluating in vivo absorption of vitamin B12. When absorption is abnormally low, the test may be repeated with addition of exogenous intrinsic factor (IF) in order to correct the IF deficiency that characterizes pernicious anemia. A dual-isotope variation provides a means of performing both stages of the test simultaneously, thereby speeding up the test and reducing dependence on complete urine collection. The dual-tracer test depends on no exchange of B12 moieties on the IF molecule. In vitro studies suggest that this exchange does take place, in a manner dependent on time, temperature, and pH. Furthermore, in vivo studies indicate that, when administered simultaneously, the absorption of unbound B12 is elevated, and IF-bound B12 is reduced, in pernicious-anemia patients, relative to the classic two-stage examination. A number of clinical studies indicate significant difficulty in resolving clinical diagnoses with the dual-tracer test. The potential weaknesses of the test discussed herein can be overcome by temporally separating the administration of the two B12 doses and by treating secondary malabsorption where it exists. An algorithm is offered for selecting the most suitable variation of the Schilling test to improve the accuracy of test results and the ease of performance.

Reliability of the dual-isotope Schilling test for the diagnosis of pernicious anemia or malabsorption syndrome.

To evaluate the dual-isotope Schilling test for the diagnosis of pernicious anemia or malabsorption syndrome, 65 studies were selected for clinical correlation. Criteria for pernicious anemia included mean corpuscular volume greater than 100 cu micrometer, serum B12 greater than 100 ng/l, megaloblastic marrow, achlorhydria, reticulocytes greater than 5% on B12 therapy, atrophic gastritis, and elevated serum antibodies to parietal cells or intrinsic factor. Criteria for malabsorption syndrome included: decreased serum B12, folate, and carotene; increased fecal fat; abnormal D-xylose absorption; abnormal radiographic and biopsy findings. 58Co-cyanocobalamin and 57Co-cyanocobalamin bound to intrinsic factor were given orally to fasting patients; 1 mg of nonradioactive B12 was injected intramuscularly within two hours. Aliquots of 24-hour urine samples were counted. If the excretion of 58Co was less than 7% and the 57Co/58Co ratio was greater than 1.7, the test indicated pernicious anemia; a ratio less than 1.7 indicated malabsorption syndrome. Sensitivity, specificity, and accuracy of the dual-isotope Schilling test were 83%, 98%, and 94% for pernicious anemia, and 67%, 90%, and 86% for malabsorption syndrome, respectively.

Dual isotope Schilling test for measuring absorption of food-bound and free vitamin B12 simultaneously.

A prototype food-bound vitamin B12 (food-B12) absorption test has been developed in which 57Co-B12 was incorporated in vitro into egg yolk (yolk-B12) and served to volunteers in 50-g cooked portions together with toast and coffee for breakfast. Six hours later, 1 mg nonlabeled B12 was given intramuscularly and 24-hour urine was collected for radioactivity measurement. In separate tests, the absorption of yolk-B12 and crystalline 57Co-B12 was equally poor in patients with pernicious anemia. However, in patients with simple gastric achlorhydria and those who had undergone gastric surgery, the assimilation of yolk-B12 was impaired greatly, whereas the absorption of crystalline radio-B12 was normal. Egg yolk labeled with 58Co-B12 was administered together with crystalline 57Co-B12 in a dual isotope test with results similar to those obtained when the tests were prepared separately. This yolk-58Co-B12 test with its ability to detect malabsorption of food-B12 may be considered as an addition to the first part of the Schilling test.

[The influence of vitamin B 12 premedication on the result of the Schilling test (author's transl)]. / Der Einfluss einer Vitamin B 12-Prämedikation auf das Ergebnis des Schilling-Tests.

The effect of previous administration of vitamin B 12 on the Schilling test was examined in 10 patients, repeating the test during and 10 days after vitamin B 12 treatment. Under vitamin B 12 medication, the patients showed a significantly decreased vitamin B 12 urinary excretion. Ten days after vitamin B 12, repeat Schilling test demonstrated comparable results with baseline values except for one patient, who persistently had a low value.

Diagnosing vitamin B12 deficiency, a common geriatric disorder.

Vitamin B12 deficiency in the elderly is a common disorder associated with an increased morbidity if it goes undetected, as often happens. Its diagnosis can be enhanced if the clinician recognizes the associated clinical features of nonspecific symptoms, glossitis, and dermatologic and neuropsychiatric abnormalities, and realizes the limitations of various tests (serum B12 assay, parietal cell and intrinsic factor antibody, mean corpuscular volume, and Schilling tests). Available data indicate it is sufficient to prescribe replacement B12 injections three or four times a year.

[Malabsorption of vitamin B 12 after gastrectomy for cancer]. / Il malassorbimento di vitamina B12 nelle gastrectomie per cancro.

The authors, after a short introduction of physiopathology, report on 17 patients who underwent a total (10 cases) or a subtotal (7 cases) gastrectomy for cancer at various times and then submitted to hemochromocytometric test and Schilling test modified by Katz and Bell. On the bases of information given by the tests, some clinical and therapeutic considerations are made.

Detection of protein bound vitamin B12 malabsorption. A case report and review of the literature.

The Schilling test is used to identify the cause of vitamin B12 malabsorption in patients with low serum vitamin B12 levels. The initial step required for vitamin B12 absorption is a process of separation from the protein complexes of food. The crystalline Co-57 vitamin B12 used in the Schilling test does not reproduce this physiologic process. Thus, a crystalline stage I Schilling test may be normal even in the face of cobalamin malabsorption. An adjunctive stage I Schilling test using Co-57 vitamin B12 bound to protein has been developed. The authors describe a patient with protein-bound vitamin B12 malabsorption whose crystalline Co-57 vitamin B12 stage I Schilling test was normal. A subsequent stage I Schilling test using Co-57 vitamin B12 bound to chicken serum revealed significant cobalamin malabsorption. A review of the history and literature of this diagnostic test using protein bound vitamin B12 is also presented.

[Cost-benefit of the Schilling test using cobalt-57]. / Costo-beneficio de la prueba de Schilling con cobalto-57.

Our purpose in the present publication is to determine the cost-benefit relation of the Schilling test used to measure the intestinal absorption of radioactive vitamin B12. The 60Co-B12 urinary excretion Schilling test was first reported in 1953, and five years later it was being performed at the National Institute of Nutrition (INNSZ) in Mexico City. It was performed in its original version until 1969 and from 1970 to 1980, the direct absorption was measured with a whole-body counter. For the last nine years we have used the Schilling test with 57Co labeled cyanocobalamin. From January 1981 through March 1990, 240 of these tests were carried out in 120 patients. The results were tabulated and compared with their clinical diagnosis. We analyzed our laboratory and labor costs. An oral dose of 0.5 micrograms of vitamin B12 labelled with 18.5 Bq of 57Co is taken by the fasting patients and two hours later one mg of standard B12 vitamin is injected. Urine is collected for 48 hours and the radioactivity is measured in a scintillation counter. Three days later the test is repeated with an additional oral dose of intrinsic factor (IF). The total expense is calculated using the following factors: the cost of the imported radioactive vitamin, IF capsules, parenteral B12 vitamin, syringes, equipment use and its depreciation, laboratory material, and salaries for the professional and administrative personnel.(ABSTRACT TRUNCATED AT 250 WORDS)